301 related articles for article (PubMed ID: 21607945)
1. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction.
André MC; Sigurdardottir D; Kuttruff S; Pömmerl B; Handgretinger R; Rammensee HG; Steinle A
Int J Cancer; 2012 Oct; 131(7):1601-10. PubMed ID: 21607945
[TBL] [Abstract][Full Text] [Related]
2. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
[TBL] [Abstract][Full Text] [Related]
3. NKG2D induces Mcl-1 expression and mediates survival of CD8 memory T cell precursors via phosphatidylinositol 3-kinase.
Wensveen FM; Lenartic M; Jelencic V; Lemmermann NA; ten Brinke A; Jonjic S; Polic B
J Immunol; 2013 Aug; 191(3):1307-15. PubMed ID: 23804716
[TBL] [Abstract][Full Text] [Related]
4. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
5. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
6. Development of memory CD8+ T cells and their recall responses during blood-stage infection with Plasmodium berghei ANKA.
Miyakoda M; Kimura D; Honma K; Kimura K; Yuda M; Yui K
J Immunol; 2012 Nov; 189(9):4396-404. PubMed ID: 23008449
[TBL] [Abstract][Full Text] [Related]
7. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
Rolle CE; Carrio R; Malek TR
Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
[TBL] [Abstract][Full Text] [Related]
8. NKG2D receptor activation of NF-κB enhances inflammatory cytokine production in murine effector CD8(+) T cells.
Whitman E; Barber A
Mol Immunol; 2015 Feb; 63(2):268-78. PubMed ID: 25089028
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic measles virus enhances antitumour responses of adoptive CD8
Chen A; Zhang Y; Meng G; Jiang D; Zhang H; Zheng M; Xia M; Jiang A; Wu J; Beltinger C; Wei J
Sci Rep; 2017 Jul; 7(1):5170. PubMed ID: 28701757
[TBL] [Abstract][Full Text] [Related]
10. NKG2D: A versatile player in the immune system.
Jelenčić V; Lenartić M; Wensveen FM; Polić B
Immunol Lett; 2017 Sep; 189():48-53. PubMed ID: 28414183
[TBL] [Abstract][Full Text] [Related]
11. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
12. Functions of NKG2D in CD8
Prajapati K; Perez C; Rojas LBP; Burke B; Guevara-Patino JA
Cell Mol Immunol; 2018 May; 15(5):470-479. PubMed ID: 29400704
[TBL] [Abstract][Full Text] [Related]
13. Memory CD8 T Cells Generated by Cytomegalovirus Vaccine Vector Expressing NKG2D Ligand Have Effector-Like Phenotype and Distinct Functional Features.
Šustić M; Cokarić Brdovčak M; Lisnić B; Materljan J; Juranić Lisnić V; Rožmanić C; Indenbirken D; Hiršl L; Busch DH; Brizić I; Krmpotić A; Jonjić S
Front Immunol; 2021; 12():681380. PubMed ID: 34168650
[TBL] [Abstract][Full Text] [Related]
14. LFA-1 defect-induced effector/memory CD8+ T cell apoptosis is mediated via Bcl-2/Caspase pathways and associated with downregulation of CD27 and IL-15R.
Ye Z; Shi M; Xu S; Xiang J
Mol Immunol; 2010 Aug; 47(14):2411-21. PubMed ID: 20569988
[TBL] [Abstract][Full Text] [Related]
15. T cells expressing the activating NK-cell receptors KIR2DS4, NKG2C and NKG2D are elevated in paroxysmal nocturnal hemoglobinuria and cytotoxic toward hematopoietic progenitor cell lines.
van Bijnen ST; Withaar M; Preijers F; van der Meer A; de Witte T; Muus P; Dolstra H
Exp Hematol; 2011 Jul; 39(7):751-62.e1-3. PubMed ID: 21554925
[TBL] [Abstract][Full Text] [Related]
16. NKG2D stimulation of CD8
Kavazović I; Lenartić M; Jelenčić V; Jurković S; Lemmermann NAW; Jonjić S; Polić B; Wensveen FM
Eur J Immunol; 2017 Jul; 47(7):1123-1135. PubMed ID: 28378389
[TBL] [Abstract][Full Text] [Related]
17. NKG2D defines tumor-reacting effector CD8
Mojic M; Shitaoka K; Ohshima C; Ucche S; Lyu F; Hamana H; Tahara H; Kishi H; Hayakawa Y
Cancer Sci; 2021 Sep; 112(9):3484-3490. PubMed ID: 34187084
[TBL] [Abstract][Full Text] [Related]
18. NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors.
Godbersen C; Coupet TA; Huehls AM; Zhang T; Battles MB; Fisher JL; Ernstoff MS; Sentman CL
Mol Cancer Ther; 2017 Jul; 16(7):1335-1346. PubMed ID: 28500232
[TBL] [Abstract][Full Text] [Related]
19. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.
Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ
J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059
[TBL] [Abstract][Full Text] [Related]
20. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
